Bayforest Capital’s Novartis NVS Stock Holding History

Bayforest Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-255	Closed	-$30.9K	–	866
2025 Q2	$30.9K	Sell	255 -498	-66%	-$56.1K	0.01%	556
2025 Q1	$83.9K	Sell	753 -2,522	-77%	-$268K	0.04%	505
2024 Q4	$319K	Buy	+3,275	New	+$349K	0.4%	31

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bayforest Capital's NVS Position: Q3 2025 in Review

Bayforest Capital sold out of Novartis (NVS) in Q3 2025, closing a stake of 255 shares — an estimated $30.9K sold.

Bayforest Capital first reported a position in NVS in Q4 2024 and held it in 3 quarters. The position peaked at $319K in Q4 2024. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

Bayforest Capital reported no remaining Novartis position as of Q3 2025 after selling out during the quarter.
Bayforest Capital sold 255 Novartis shares in Q3 2025, an estimated $30.9K.
Bayforest Capital first reported a position in Novartis in Q4 2024 and held it in 3 quarters.
Bayforest Capital's Novartis position peaked at $319K in Q4 2024.
1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on Bayforest Capital's 13F filing for Q3 2025, filed 24 Oct 2025.